Objectives: Rifampicin potentiates the activity of aminoglycosides (AGs) versus Pseudomonas aeruginosa by targeting the AmgRS two-component system. In this study we examine the impact of rifampicin on the AG susceptibility of cystic fibrosis (CF) lung isolates of P. aeruginosa and the contribution of AmgRS to AG resistance in these isolates.
Introduction
Pseudomonas aeruginosa is a common lung pathogen and a major cause of morbidity and mortality in patients with cystic fibrosis (CF).
1 Aminoglycosides (AGs) are commonly employed in the management of P. aeruginosa lung infections in CF 2 although their use is complicated by the toxicity of these agents 3 and development of resistance in the infecting P. aeruginosa. 4 To address these issues, AG-potentiating agents have previously been sought, with a focus on those that target AG resistance mechanisms. 5 One AGpotentiating agent, rifampicin, was found to target the envelope stress-responsive AmgRS two-component system (TCS), 6 ,7 a demonstrated determinant of AG resistance in laboratory 6 and clinical 8 isolates of P. aeruginosa that also mediates the AG induction of the AG resistance-promoting MexXY multidrug efflux system. 7 Interestingly, rifampicin only reduced resistance to a subset of AGs, the 4,5-linked AGs neomycin and paromomycin, in a WT laboratory strain and some clinical isolates, although it did increase susceptibility to all AGs, including the more clinically relevant 4,6-linked AGs tobramycin, amikacin and gentamicin, in a clinical isolate in which resistance was attributable to AmgRSdependent up-regulation of MexXY. 5 To better understand its utility in potentiating AG activity versus clinical strains of P. aeruginosa, the impact of rifampicin on the AG susceptibility of a large collection of AG-resistant CF lung isolates was assessed, as was the contribution of AmgRS to AG resistance in these isolates.
Materials and methods

Bacterial strains
Strains K3518-K3691 are tobramycin-resistant CF lung isolates of P. aeruginosa, either internationally collected epidemic strains or strains obtained (with consent) from patients attending the Calgary Adult Cystic Fibrosis Clinic (see Table S1 , available as Supplementary data at JAC Online). Permission from the Conjoint Health Region Ethics Board of the University of Calgary was granted for the collection and analysis of these strains (REB 15-0854). Strains K3716, K3710, K3712, K3715, K3713 and K3714 are DamgR derivatives of CF strains K3519, K3524, K3527, K3528, K3530 and K3533, respectively.
Construction of DamgR derivatives of P. aeruginosa
Despite repeated attempts, construction of amgR deletion derivatives of several tobramycin-resistant CF isolates of P. aeruginosa using the previously described pEX18Tc::DamgR suicide vector 6 was unsuccessful. Difficulties in using pEX18Tc to generate deletions in clinical strains has been noted previously 9 and likely stems from the need to simultaneously select for conjugation of the vector into the strain being mutated and its integration into the chromosome (pEX18Tc lacks a P. aeruginosa origin of V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. replication), either of which may be less efficient in clinical strains. To address this issue, a pEX18Tc::DamgR derivative carrying a temperaturesensitive P. aeruginosa origin of replication was constructed, permitting vector conjugation and integration to be carried out separately and sequentially, the former at the permissive temperature and the latter at the non-permissive temperature. Thus, a 1.9 bp PstI fragment carrying a temperature-sensitive origin of replication, mSF ts1 , was excised from plasmid pSS255 10 and inserted into the PstI site of pEX18Tc::DamgR, yielding pEX18Tc::DamgR-Ts. The vector was introduced into Escherichia coli strain S17-1 (selected on 10 mg/L tetracycline) for subsequent mobilization into the clinical strains using a previously described protocol, 8 with modifications. Briefly, aliquots of overnight cultures of S17-1 carrying pEX18Tc::DamgR-Ts (700 lL) and individual clinical isolates (300-600 lL) were mixed and spotted onto L-agar plates and incubated for 6 h at 30 C. Following resuspension of the mating mixtures, transconjugants were selected at 30 C on L-agar plates containing tetracycline (20-100 mg/L) and chloramphenicol (5 mg/L; to counter-select E. coli), the exact tetracycline concentration being determined empirically for each strain being mutated.
Transconjugants showing the expected temperature-sensitive phenotype (i.e. growth in tetracycline-containing medium at 30 C, but not at 42 C) were cultured overnight in tetracycline-containing L-broth at 30 C, plated on tetracycline-containing L-agar plates and then cultured for 1-2 days at 42 C to select for plasmid integration into the chromosome. Tetracyclineresistant colonies were streaked onto sucrose-containing [10% (v/v)] L-agar plates, incubated at 42 C for 1-2 days and sucrose-resistant colonies were then screened for deletion of amgR using colony PCR as described previously. 8 
Antibiotic susceptibility testing
The susceptibility of P. aeruginosa to AGs was assessed using the 2-fold serial microtitre broth dilution method described previously. 11 MICs were recorded as the lowest concentration of antibiotic inhibiting visible growth after 18 h of incubation at 37 C. Where indicated, rifampicin was included at ½ MIC for the strains being tested.
Results and discussion
Rifampicin potentiates AG activity versus clinical strains of P. aeruginosa
In a previous study, rifampicin was shown to potentiate the activity of 4,5-linked AGs versus the few clinical strains that were examined, with additional potentiation of 4,6-linked AGs seen in a single isolate. 5 To get a better sense of rifampicin's utility in potentiating AG activity versus clinical P. aeruginosa strains, the impact of rifampicin on AG activity versus 45 CF lung isolates provisionally identified as tobramycin resistant was assessed. This included several internationally recognized epidemic strains of P. aeruginosa and multiple isolates (median 2/patient) from 12 patients with genotypically distinct infections followed by the Calgary Adult Cystic Fibrosis Clinic. 12 Initially, the susceptibility of these strains to AGs, including tobramycin, was determined in the absence of rifampicin, generally confirming the original tobramycin resistance and, indeed, revealing elevated MICs of multiple AGs (Table 1) . At ½ MIC, rifampicin had a variable impact on AG susceptibility that varied with strain and AG ( Table 1) . As expected, rifampicin had the greatest impact on neomycin, a representative 4,5-linked AG, both in terms of the number of strains for which rifampicin yielded a 4-fold decline in MIC (36/45) and the magnitude of the fold decrease (20/45 showed decreases 16-fold, with decreases of up to 128-fold seen). Indeed, in several instances it was the only AG whose activity was potentiated 4-fold (9/45), reflecting what was seen earlier in the WT strain K767. 5 Instances of rifampicin-promoted reductions in AG MICs 4-fold were less common though still substantial for the 4,6-linked AGs (tobramycin, 22/45 strains; amikacin, 22/45; gentamicin, 24/45). The magnitude of the 4,6-linked AG MIC decrease prompted by rifampicin was also generally lower than that seen for neomycin (typically ,16-fold; Table 1 ). For most strains, there was 4-fold potentiation of at least two AGs (32/45) and a few examples where no AG potentiation was seen (4/45), with instances of rifampicin potentiation 4-fold for all of the 4,6-linked AGs less common (12/45) and for all AGs even less so (10/45). While rifampicin appears to have a substantial impact on AG susceptibility in the CF isolates, with a marked impact on all clinically relevant 4,6-linked AGs in about a quarter of the isolates examined, the wide variability in magnitude and AG impacted in each strain doubtless speaks to the multiplicity of resistance mechanisms that can contribute to AG resistance in P. aeruginosa 13 and their presumably variable susceptibility to rifampicin action.
AmgRS contributes to AG resistance in clinical strains of P. aeruginosa
Rifampicin potentiation of AG activity was previously shown to be dependent on the presence of AmgRS, 5 an indication that it was directly or indirectly targeting this TCS. To gain some insights into the nature of the rifampicin potentiation of AGs seen in the current study, as well as to assess the contribution of AmgRS to AG resistance in CF isolates generally, attempts were made to delete amgRS in the CF isolates and to determine the impact on both AG resistance and rifampicin potentiation of AG activity. In focusing initially on strains K3518-K3540, and despite repeated attempts, amgR deletions were achieved in only six isolates (Table 2 ). This reflects an ongoing problem with deletion construction in clinical isolates and may be explained by conjugation and/or recombination deficiencies in such isolates, the latter potentially related to DNA sequence variations between the plasmid-borne deletion construct and the corresponding genomic region of the clinical isolates. Nonetheless, loss of amgR had a substantive impact on AG resistance in the CF isolates for which deletions could be engineered, with MIC decreases 4-fold seen for at least one AG in 6/6 strains and for all 4,6-linked AGs in 3/6 strains ( Table 2) , an indication that AmgRS is contributing to AG resistance in these isolates. In one case in particular, K3710, the MICs of all four AGs tested decreased a minimum of 16-fold upon loss of amgR (Table 2) . Surprisingly, however, given the earlier link between rifampicin potentiation and AmgRS, in most cases and for most AGs, rifampicin still reduced AG MICs for the deletion derivatives, in several instances more so than for the AmgR ! parental strains. Thus, rifampicin can clearly impact AG susceptibility independent of AmgRS. The observation, too, that in some instances rifampicin only modestly potentiated AG activity in an AmgR ! strain despite a major contribution of AmgRS to AG resistance [e.g. strain K3524 where rifampicin increased susceptibility to amikacin and gentamicin 2-and 4-fold, respectively, while loss of amgR in this strain (see K3710) reduced MICs of these AGs 16-and 32-fold] indicates that rifampicin is unable to reverse all examples of AmgRS-mediated AG resistance. Thus, while rifampicin does have a broad ability to increase susceptibility to individual AGs in clinical strains of Potentiation of aminoglycoside activity JAC P. aeruginosa, its mode(s) of action appear to be varied and, for the most part, undefined.
